Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label aflibercept safety and quality-of-life study in metastatic colorectal cancer previously treated with oxaliplatin
2011-005724-17Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aflibercept in colorectal cancer (CRC), sponsored by Sanofi. Primary endpoint: Number of participants reporting adverse events. Started Mar 2012; status: completed.
02
Drugs
aflibercept
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2011-005724-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005724-17.